Interpreting Important Clinical Trials in Schizophrenia: Evaluating the Effectiveness of Antipsychotics

Joseph McEvoy, MD
Associate Professor of Psychiatry
Behavioral Sciences
Duke University Medical Center
Deputy Clinical Director
John Umstead Hospital
Butner, NC

Dr. McEvoy is currently an Associate Professor of Psychiatry and Behavioral Sciences (tenured) at Duke University Medical Center, and the Deputy Clinical Director of John Umstead Hospital in Butner, NC.

He received his M.D. degree at Vanderbilt University Medical School, did two years of Internal Medicine training at the University of Utah Hospital System, and completed his Psychiatry training at Vanderbilt. He is Board-certified in Psychiatry. He is a Distinguished Fellow of the American Psychiatric Association.

Dr. McEvoy has served on the faculty of Vanderbilt University, the University of Pittsburgh, and Duke University. He has over 90 refereed publications, primarily focusing on psychopharmacology and biological psychiatry. He has twice (1996 and 1999) edited the Expert Consensus Guidelines for the Treatment of Schizophrenia. He has served as Co-Principal Investigator and Project Medical Officer for the CATIE (Clinical Antipsychotic Trials for Intervention Effectiveness) and CAFÉ (Comparison of Atypicals for First Episode) trials, and currently continues in a similar role in the NIMH-supported Schizophrenia Trials Network.

The Duke Psychiatry residents have twice (1999 and 2002) selected Dr McEvoy for their Honored Teacher Award.

Individual Disclosure Statements

Dr. Stroup disclosed that he is a member of the speakers bureau and consultant for Lilly and Pfizer and a consultant for Janssen, which could be perceived as a potential conflict of interest in his presentation. Dr. Stroup further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation.

Dr. McEvoy disclosed that he is a grant/research support recipient for AstraZeneca and is a grant/research support recipient and honoraria recipient for Bristol-Myers Squibb, Janssen, Lilly and Pfizer, which could be perceived as a potential conflict of interest in his presentation. Dr. McEvoy further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation.

Dr. Citrome disclosed that he is a member of the speakers' bureau, grant/research support recipient, consultant, and stock holder for Eli Lilly and Pfizer; a speakers' bureau and grant/research support recipient for Pfizer; a grant/research support recipient and stockholder for Janssen and Bristol-Myers Squibb; a member of the speakers' bureau and stockholder for Abbott Laboratories; a grant/research support recipient for Barr Laboratories; a consultant for Jazz Pharmaceuticals; a consultant and stockholder for GlaxoSmithKline; and a stockholder for Merck, which could be perceived as a potential conflict of interest in his presentation. Dr. Citrome further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation.

Staff Disclosure Declarations

The employees of Scinexa Medical Education Company and ArcMesa Educators have no financial relationships to disclose.

Printer settings may vary. Please use landscape layout option.

	Chair
		Scott Stroup, MD, MPH Associate Professor of Psychiatry Adjunct Associate Professor of Social Medicine University of North Carolina at Chapel Hill Chapel Hill, NC Dr. Stroup is Associate Professor of Psychiatry at the University of North Carolina at Chapel Hill. He is a Co-Principal Investigator of the schizophrenia trial of the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) program and is an attending psychiatrist in the UNC Hospitals Schizophrenia Treatment and Evaluation Program. Dr. Stroup is a co-editor of the new Textbook of Schizophrenia published by the American Psychiatric Press, Inc.
	Faculty
		Joseph McEvoy, MD Associate Professor of Psychiatry Behavioral Sciences Duke University Medical Center Deputy Clinical Director John Umstead Hospital Butner, NC Dr. McEvoy is currently an Associate Professor of Psychiatry and Behavioral Sciences (tenured) at Duke University Medical Center, and the Deputy Clinical Director of John Umstead Hospital in Butner, NC. He received his M.D. degree at Vanderbilt University Medical School, did two years of Internal Medicine training at the University of Utah Hospital System, and completed his Psychiatry training at Vanderbilt. He is Board-certified in Psychiatry. He is a Distinguished Fellow of the American Psychiatric Association. Dr. McEvoy has served on the faculty of Vanderbilt University, the University of Pittsburgh, and Duke University. He has over 90 refereed publications, primarily focusing on psychopharmacology and biological psychiatry. He has twice (1996 and 1999) edited the Expert Consensus Guidelines for the Treatment of Schizophrenia. He has served as Co-Principal Investigator and Project Medical Officer for the CATIE (Clinical Antipsychotic Trials for Intervention Effectiveness) and CAFÉ (Comparison of Atypicals for First Episode) trials, and currently continues in a similar role in the NIMH-supported Schizophrenia Trials Network. The Duke Psychiatry residents have twice (1999 and 2002) selected Dr McEvoy for their Honored Teacher Award.
		Leslie Citrome, MD, MPH Director, Clinical Research and Evaluation Facility Nathan S Kline Institute for Psychiatric Research Professor of Psychiatry New York University School of Medicine Orangeburg, NY Dr. Citrome is Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and Professor of Psychiatry at the New York University School of Medicine. Dr. Citrome is involved as Principal Investigator, Co-Investigator, and Collaborator on a number of ongoing projects centering on psychopharmaceutical approaches to schizophrenia and bipolar disorder, including new and novel medications, management of treatment refractory schizophrenia, and the management of aggressive and violent behavior. He is also an active member of the Medication Utilization and Outcomes Research Program that focuses on the practice of psychiatry within the 16 hospitals operated by the New York State Office of Mental Health. He is the author or co-author of over 200 research reports, reviews, and abstracts in the scientific literature, and has lectured extensively throughout the USA, Canada, Europe, and Asia.
	Disclosure Policy It is the policy of the University of California, Irvine School of Medicine and the University of California CME Consortium to ensure balance, independence, objectivity and scientific rigor in all CME activities. All presentations have been peer reviewed for evidence-base and fair balance. Individual Disclosure Statements Dr. Stroup disclosed that he is a member of the speakers bureau and consultant for Lilly and Pfizer and a consultant for Janssen, which could be perceived as a potential conflict of interest in his presentation. Dr. Stroup further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation. Dr. McEvoy disclosed that he is a grant/research support recipient for AstraZeneca and is a grant/research support recipient and honoraria recipient for Bristol-Myers Squibb, Janssen, Lilly and Pfizer, which could be perceived as a potential conflict of interest in his presentation. Dr. McEvoy further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation. Dr. Citrome disclosed that he is a member of the speakers' bureau, grant/research support recipient, consultant, and stock holder for Eli Lilly and Pfizer; a speakers' bureau and grant/research support recipient for Pfizer; a grant/research support recipient and stockholder for Janssen and Bristol-Myers Squibb; a member of the speakers' bureau and stockholder for Abbott Laboratories; a grant/research support recipient for Barr Laboratories; a consultant for Jazz Pharmaceuticals; a consultant and stockholder for GlaxoSmithKline; and a stockholder for Merck, which could be perceived as a potential conflict of interest in his presentation. Dr. Citrome further discloses he will not be discussing the use of any unlabelled/approved drugs or devices in his presentation. Resolution All materials have been reviewed for evidence base and fair balance. Staff Disclosure Declarations The employees of Scinexa Medical Education Company and ArcMesa Educators have no financial relationships to disclose. Printer settings may vary. Please use landscape layout option. Copyright © 2006 Scinexa, LLC / CMEdiscovery.com. All rights reserved.

Chair

Faculty

Disclosure Policy

Individual Disclosure Statements

Resolution

Staff Disclosure Declarations